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Severe asthma (SA) presents in about 3%–5% of adult asthmatics and is responsible for over 
60% of asthma-related medical expenses, posing a heavy socioeconomic burden. However, to 
date, a precise definition of or clear diagnostic criteria for SA have not been established, and 
therefore, it has been challenging for clinicians to diagnose and treat this disease. Currently, 
novel biologics targeting several molecules, such as immunoglobulin E, interleukin (IL)5, and 
IL4/IL13, have emerged, and many new drugs are under development. These have brought a 
paradigm shift in understanding the mechanism of SA and have also provided new treatment 
options. However, we need to agree on a precise definition of and its diagnostic criteria for 
SA. Additionally, it is necessary to explain the diagnostic criteria and to summarize current 
standard and additional treatment options. This review is an experts' opinion on SA from the 
Korean Academy of Asthma, Allergy, and Clinical Immunology, the Working Group on Severe 
Asthma, and aims to provide a definition of and diagnostic criteria for SA, and propose future 
direction for SA diagnosis and management in Korea.
Keywords: Severe asthma; biologics; diagnosis; eosinophil; expert opinion; IgE; treatment, 
IL5; IL4
INTRODUCTION
Asthma is a highly prevalent airway disease. Severe asthma (SA) is a life-threatening 
condition that affects only a minor percentage of the patient population, but which 
accounts for more than 60% of the total asthma-related medical expenses, imposing a 
heavy socioeconomic burden.1 The appropriate management of SA remains challenging. 
Insights into the unmet needs of treating SA have facilitated understanding of the disease 
pathophysiology, resulting in development of novel biological treatments and a paradigm 
shift in the management of SA.
Most clinicians currently adopt the latest SA definition proposed by the European Respiratory 
Society (ERS)/American Thoracic Society (ATS) in 2014: asthma that requires high-dose 
inhaled corticosteroids (ICS) plus a second controller and/or systemic corticosteroids (SCS) 
to prevent it from becoming uncontrolled, or asthma that remains uncontrolled despite 
such therapy.2 Recently, the ERS/ATS published new guidelines for managing SA, including 
the use of novel drugs.3 Nevertheless, clinicians remain unsure when and for whom biologic 
treatment should be considered. Additionally, it is not clear which biologics should be 
tried as a first-line option. Therefore, a practical guideline for SA is required that considers 
the distinct regional circumstances and newly available biologics. The members of the 
Korean Working Group for Severe Asthma from the Korean Academy of Allergy and Clinical 
Immunology (KAAACI) have formulated such a guide, thoroughly reviewing the definition, 
epidemiology, diagnosis, phenotyping, and general controller medications of SA, and 
providing practical guidance for the management of SA, addressing the role of emerging 
therapies, defining potential responders.
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METHODS
Target users
The target users of this document are specialists in allergy and respiratory medicine 
managing adult asthmatic patients. General internists and primary care physicians may 
also benefit from this document as they need to decide when it is appropriate to refer their 
patients to specialists.
Development methods
The Working Group for Severe Asthma of the KAAACI undertook this review of difficult-to-
treat and SA. The members of this Working Group are specialists in allergy, pulmonology, 
and immunology. Key topics were selected by the representative members of the Working 
Group, and all participating members were assigned a topic based on their expertise or 
interest. Literature reviews included comprehensive domestic and international electronic 
database searches. Data from relevant studies were summarized and the document was 
constructed through a series of face-to-face meetings, and the completed document 
was reviewed by 2 asthma experts outside the Working Group. This expert opinion paper 
comprises 4 parts: 1) definition, prevalence, and burden of SA; 2) diagnosis of SA; 3) 
treatment of SA; and 4) specific situations.
DEFINITION, PREVALENCE, AND BURDEN OF SA
Evolution in the understanding of asthma severity
The severity of asthma has been evaluated differently across studies based on various factors, 
such as lung function, clinical symptoms, or medication for decades. In 1995, the Global 
Initiative for Asthma (GINA) guidelines suggested a classification of asthma severity based 
on its clinical features, including the degree of symptoms and exacerbations, frequency of 
nighttime symptoms, consumption of a reliever, limitation of physical activities, and lung 
function. However, clinicians became aware of asthma subgroups whose disease was not 
easily controlled with conventional treatment, thus giving rise to the current concept of SA. 
Several nomenclatures and definitions were used to describe this problematic population 
(Table 1). Since previous guidelines did not take into account the treatment response when 
assessing asthma severity, an ATS-sponsored workshop presented the diagnostic criteria of 
“refractory asthma” in 2000.4 It was a combination of medication requirements to achieve 
controlled status, and had other minor characteristics in terms of symptoms, exacerbation 
history, and airflow limitation.4 In 2009, the World Health Organization meeting suggested 3 
subgroups of SA5: 1) untreated SA; 2) difficult-to-treat SA; and 3) treatment-resistant SA. The 
last group was defined as uncontrolled asthma despite use of the highest level of treatment 
and controlled only by maintaining the highest level of treatment.5 This definition was also 
similar to an international consensus from the Innovative Medicine Initiative and ERS/ATS.2,6 
Accordingly, the essential components defining SA include the level of symptom control, 
future risk of adverse outcomes, and medication required to control symptoms. The control 
status of symptoms has been determined by either impact on daily life or the exacerbation 
history. Risk factors for poor asthma outcomes consist of fixed airflow limitation and 
side-effects of medications, in addition to the exacerbation itself. Finally, the required 
medication should be maximally optimized therapy after treating modifiable risk factors 
and comorbidities. In 2019, GINA reported guidelines regarding the term “difficult-to-treat 
asthma and SA.”7 In the guidelines, “uncontrolled asthma,” “difficult-to-treat asthma,” and 
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“SA” are defined separately, emphasizing the need for several management steps before 
making a final diagnosis of SA.7
Prevalence of SA
Given the historical changes in the definitions of SA, its prevalence varies depending on the 
definitions applied, defined populations, and methodologies used. In population-based 
studies, the Asthma Insights and Reality surveys showed that severe persistent asthma in 
adults ranged from 12.5% in the Asia-Pacific region to 20.5% in Western Europe, using the 
GINA severity classification and symptom severity index.8,9 In hospital-based studies, severe 
persistent asthma prevalence was reported as 3.9%-7.8% based on clinicians' judgment and 
the GINA severity classification.10,11 Thus, heterogeneous SA definitions may have affected the 
estimation of its true prevalence.
As the definition of SA is refined, recent population-based asthma studies have demonstrated 
that the prevalence of SA depends on the definition used, from 3.6% (Severe Asthma 
Research Program), to 4.8% (ERS/ATS Taskforce), and 6.1% (GINA), among subjects with 
current asthma.12 The current definition of SA emphasizes maximal optimal treatment, 
including drug adherence and management of comorbidities. A few studies have shown the 
precise prevalence of SA using this approach. In data from Danish nationwide registers, 8.1% 
of the patients identified were classified as having SA; their symptoms could be controlled 
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Table 1. Published definitions of severe asthma
Guidelines Definition Required medications Additional details
ATS (2000) •  Refractory asthma requires 1 or both major 
criteria and 2 minor criteria
• Major criteria • Minor criteria; at least 2 of following categories
1)  Continuous or near-continuous 
(≥ 50% of the year) OCS
1)  Requirement for daily treatment with additional 
controller
2) High-dose ICS 2) Requirement for short-acting inhaled β2-agonist
3) Persistent airway obstruction
4) 1 or more urgent care visits for asthma per year
5) 3 or more oral steroid “bursts” per year
6)  Prompt deterioration with ≤ 25% reduction in oral 
or ICS dose
7) Near-fatal asthma event in the past
WHO (2009) • Treatment-resistant severe asthma •  High-dose ICS or a high-dose ICS–
LABA combination
• Frequent or chronic use of SCS
•  Level of control assessed based on following categories:
1)  “Control” is not achieved despite highest 
level treatment
2)  “Control” maintained only with highest 
level treatment
1) Daytime symptoms
2) Limitations on activities
3) Nocturnal symptoms/awakenings
4) Need for short-acting inhaled β2-agonist
5) Lung function
6) Exacerbations
IMI (2011) •  Refractory asthma despite high-intensity 
treatment
• High-dose ICS with or without SCS • Uncontrolled and/or frequent (≥ 2/year) exacerbations
ERS/ATS (2014) •  Asthma that requires high-intensity 
medication to prevent it becoming 
“uncontrolled” or that remains 
“uncontrolled” despite therapy
•  Controlled asthma that worsens on tapering 
of these high doses of ICS or SCS (or 
additional biologics)
•  Medications for GINA steps 4–5 
asthma for the previous year or
• SCS for ≥ 50% of the previous year
• Uncontrolled asthma; at least 1 of the following:
1) Poor symptom control
2) Frequent severe exacerbations
3) Serious exacerbations
4) Airflow limitation
GINA (2019) •  Uncontrolled asthma despite adherence to 
maximal optimized therapy and treatment 
contributory factors
•  Asthma worsens when high-dose treatment 
is decreased
•  Medications for GINA steps 4–5 
asthma
•  Uncontrolled asthma; at least 1 of the following 
categories:
1) Poor symptom control
2) Frequent or serious exacerbations
• Good adherence and inhaler technique
ATS, American Thoracic Society; WHO, World Health Organization; IMI, Innovative Medicine Initiative; ERS, European Respiratory Society; GINA, Global Initiative 
for Asthma; ICS, inhaled corticosteroids; LABA, long-acting β2-agonists; OCS, oral corticosteroids; SCS, systemic corticosteroids.
with high-dose ICS and second controllers, including omalizumab.13 Based on 65 Dutch 
pharmacy databases, 3.6% of all adults with asthma were controlled by high-dose ICS plus at 
least 2 consecutive 3-month prescriptions of oral corticosteroids (OCS).14
In Korea, the number of reliable population studies exactly meeting the SA definition is limited. 
Nonetheless, there are some indirect estimates. A study using nationwide claims data showed 
that approximately 11% of patients had SA, defined as those using high-dose ICS.15 A survey 
of Korean allergy or pulmonology specialists showed that about 13% of their patients seemed 
to have SA.16 A recent study using national health claims data reported that the SA prevalence 
in Korea had increased from 3.5% to 6.1% over a decade.17 Future investigation on the 
epidemiology of SA is needed with the establishment of a definition of SA.
Mortality, OCS use, and quality of life
From a claims database in France in 2012, the 3-year cumulative mortality rate was markedly 
higher in SA patients than in patients without asthma (7.1% vs. 4.5%).18 The asthma mortality 
data from Korea were initially reported as 0.21 per 100,000 population in 1995, and then 
decreased to 0.08 in 2006 and 0.04 in 2012.19 In contrast, a recent analysis of heath claims 
data and the Statistics Korea database showed that asthma mortality had increased over a 
decade, with the highest mortality due to SA.17
Although long-term OCS use in SA patients causes numerous side-effects, OCS is widely 
used as controller or exacerbation drugs for SA. The rate of long-term OCS use in SA patients 
varies across countries (21.4%–71.9%).20 In the Korean Severe Asthma Registry, 60.1% 
of patients at GINA step 5 took OCS continuously.21 A population-based matched cohort 
study from Korea revealed that long-term use of SCS was associated with an increased 
mortality risk in a dose-dependent manner in patients with asthma.22 Moreover, quantitative 
studies reported that exacerbation of asthma and long-term OCS-use negatively impacted 
professional life and made maintaining a normal life challenging.23
Healthcare use and costs
The estimated healthcare use and costs of treatment for SA are greater than those for non-SA. 
While fewer than 10% of all individuals with asthma have SA, their healthcare accounts for at 
least 60% of all asthma-related healthcare costs.24 According to a Korean claims database, the 
annual healthcare cost for SA patients was $1,635, 9.4 times higher than that for patients with 
mild asthma ($174), and 40.8% of the healthcare cost was due to asthma exacerbation.25 The 
overall asthma-related healthcare cost has increased over years, with the highest cost related 
to SA.17 Recurrent exacerbations and uncontrolled asthma are also related to higher asthma-
related medical costs.26 Moreover, the cost of high-dose OCS users increased more than 
twice as much as that of low-dose OCS users. This might be directly related to OCS-induced 
morbidities and adverse events.
Pathogenesis of SA
Type 2 inflammation in asthma refers to asthmatics who show eosinophilic, and/or allergic 
airway inflammation. Identification of sputum eosinophil and/or high fractional exhaled 
nitric oxide (FeNO) is evidence of eosinophilic airway inflammation. Sensitization to 
common inhalant allergens in a skin-prick test or serum allergen-specific immunoglobulin E 
(IgE) tests implies allergic or atopic features of asthma. Recently, the focus on “type 2” rather 
than “Th2” asthma reflects the important contribution of innate lymphoid type 2 cells (ILC2) 
and other non-classic Th2 cells, in addition to the original Th2 cells, to the type 2 cytokine 
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milieu. On the other hand, SA without type 2 features is currently defined as the “apparent” 
absence of type 2 cytokines and their downstream signatures. Detailed information on the 
mechanisms of type 2 SA and non-type 2 SA and other mechanisms, including corticosteroid 
(CS) resistance, airway remodeling, smoking, and air pollution, which also contribute to the 
evolution of SA, are provided in Supplement S1.
DIAGNOSIS OF SA
There are 3 steps in diagnosing SA (Fig. 1): 1) determining uncontrolled asthma; 2) defining 
and evaluating difficult-to-treat asthma (confirmation of an asthma diagnosis, correction of 
modifiable risk factors, and controlling comorbidities); 3) optimizing treatments in difficult-
to-treat asthma. A diagnosis of SA is eventually made when asthma remains poorly controlled 
at 3-6 months after treatment optimization.
Determination of uncontrolled asthma
In GINA 2019, the asthma control status should be assessed in terms of asthma symptom 
control and risk factors for future poor outcomes, particularly exacerbation.7 Uncontrolled 
915https://e-aair.org https://doi.org/10.4168/aair.2020.12.6.910
Evaluation and Management of Severe Asthma
• Uncontrolled asthma symptom (3 or 4 of criteria)
- ≥ 2 daytime symptoms/weeks in the past 4 weeks
- Any night-waking in the past 4 weeks
- Reliever used ≥ 2 times/week in the past 4 weeks
- Any activity limitation in the past 4 weeks
                                                                           or
• Partly controlled asthma symptom (1 or 2 criteria) plus one risk factor for poor outcome
- Reduced lung function (FEV1 predicted value ≤ 80%)
- History of asthma exacerbation (oral corticosteroid bursts ≥ 2/year or hospitalization ≥ 1/year)




Consider referral to an asthma specialist or asthma specialty center
• Confirmation of asthma diagnosis
Consider examinations for differential diagnosis: chest CT, bronchoscopy, laryngoscopy,
serum ANCA, skin prick test, or serum specific IgE to Aspergillus




- Exposure to sensitized allergen or stimuli
    : environment control, occupational stimuli/work-related symptoms, pets
• Control of comorbidities
- CRS, GERD, OSA, obesity, depression/anxiety disorder
Consider referral to an asthma specialist or asthma specialty center
• Assessment of phenotype
: blood eosinophils, sputum eosinophils, FeNO, skin prick test, and/or specific IgE test
• Type 2 inflammation  (one or more criteria)
- Blood eosinophils ≥ 150/µ
- Sputum eosinophils ≥ 2%
- FeNO ≥ 20 ppb
- Allergen-driven





Fig. 1. Approach to uncontrolled, difficult-to-treat, and severe asthma. 
ANCA, anti-neutrophil cytoplasmic antibodies; FEV1, forced expiratory volume in 1 second; GINA, Global Initiative for Asthma; ICS, inhaled corticosteroids; CRS, 
chronic rhinosinusitis; GERD, gastroesophageal reflux disease; OSA, obstructive sleep apnea; FeNO, fractional exhaled nitric oxide; CT, computed tomography; 
IgE, immunoglobulin E.
asthma symptoms are indicated when 3 or 4 of the following criteria have been fulfilled 
over the past 4 weeks: 1) daytime symptoms more than twice a week; 2) any night waking 
due to asthma in the past 4 weeks; 3) symptom relievers were used more than twice a week; 
and 4) any activity limitation. In addition to uncontrolled symptoms, although reduced 
lung function and a history of asthma exacerbation are important risk factors for poor 
outcomes,27 symptom perception showed a poor correlation with lung function.28 Therefore, 
lung function measurements can be considered as an objective tool when asthma control is 
assessed. In Korea, the National Health Insurance Service, the only public healthcare service 
provider, emphasizes the importance of lung function tests and annually evaluates the rate of 
lung function tests to assure good quality asthma management. Moreover, the lung function 
test is widely available in primary care clinics in Korea. Accordingly, we recommend that lung 
function should be considered to determine uncontrolled asthma. Therefore, uncontrolled 
asthma includes partly controlled symptoms (1 or 2 of above criteria) plus 1 of the following 
risk factors for poor outcomes: 1) reduced lung function (forced expiratory volume in 
1 second [FEV1] predicted value ≤ 80%); 2) history of asthma exacerbations (serious 
exacerbation: OCS bursts ≥ 2/year or hospitalization ≥ 1/year).
Definition and evaluation of difficult-to-treat asthma
Difficult-to-treat asthma is defined when asthma is uncontrolled despite GINA step 4 or 5 
treatment (Fig. 1). During the treatment optimization period, physicians should check the 
following: 1) confirming the asthma diagnosis; 2) correcting modifiable risk factors; and 3) 
controlling comorbidities. Physicians are also recommended to consider referral of patients 
with difficult-to-treat asthma to asthma specialists or asthma specialty centers. We have 
included a checklist for real practice use (Table 2).
Confirming asthma diagnosis
The diagnosis of asthma should be confirmed based on the patient's clinical history and 
diagnostic tests before diagnosing SA. Differential diagnoses should be considered according 
to patient age. For patients <40 years old, chronic upper airway cough syndrome, vocal cord 
dysfunction (VCD), hyperventilation, bronchiectasis, congenital heart diseases, or foreign 
body aspiration should be distinguished from asthma. For patients >40 years old, VCD, 
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Table 2. Checklist to distinguish ‘severe asthma’ from ‘difficult-to-treat asthma’
Checklist
Is the patient a current smoker? Have you encouraged him/her to quit smoking?
Do you check how well the patient uses the inhaler and educate them on how to use it properly (at each visit)?
Do you understand the factors that keep patients not adherent to their medications?
Are there any adverse events due to asthma medications? (e.g., oral candidiasis, cough, hoarseness, dry mouth, or palpitation)
Has the patient informed of avoidance of the sensitized allergens or non-specific stimuli?
Environment control (HDM, pollens, molds, fine dust, air pollution, cold air, or other seasonal factors)
Occupational stimuli/work-related symptoms
Pets (dogs, cats, birds)
Drug adverse effects (e.g., cough, chest tightness, or dyspnea due to aspirin, ACEi, or β-blockers)
Does the patient need to be encouraged to exercise or lose weight?
Have you ever considered assessing and managing the comorbidities of the patient?
Chronic rhinosinusitis (with or without nasal polyps) by imaging studies (X-ray or CT scan of the PNS)
GERD by endoscopy or preemptive treatment with proton pump inhibitors
Obstructive sleep apnea by polysomnography
Obesity
Psychological distress (anxiety and depression)
Structural lung diseases (COPD or bronchiectasis) by imaging studies (chest CT scan)
HDM, house dust mites; ACEi, angiotensin-converting enzyme inhibitors; PNS, paranasal sinuses; GERD, gastroesophageal reflux disease; COPD, chronic 
obstructive pulmonary diseases; CT, computed tomography.
hyperventilation, chronic obstructive pulmonary disease (COPD), bronchiectasis, heart 
failure, medication-related cough (for example, angiotensin-converting enzyme inhibitors), 
parenchymal lung diseases, pulmonary embolism, and central airway obstruction should 
be considered as differential diagnoses of difficult-to-treat asthma. Furthermore, for some 
specific diseases, such as eosinophilic granulomatosis with polyangiitis (EGPA), allergic 
bronchopulmonary aspergillosis (ABPA), and chronic eosinophilic pneumonia, asthma is 
included in their diagnostic criteria. For differential diagnosis, clinicians should consider 
appropriate examinations, such as chest computed tomography, bronchoscopy, laryngoscopy, 
serum anti-neutrophil cytoplasmic antibodies, and serum specific IgE to Aspergillus.
Correcting modifiable risk factors
Modifiable risk factors should be corrected before diagnosing SA. Modifiable risk factors 
include smoking, incorrect inhaler technique, medication non-adherence, environmental 
exposure to sensitized allergens, or non-specific stimuli. Detailed information is provided 
in Supplement S2.
Controlling comorbidities
Comorbidities should be controlled before diagnosing SA. Comorbidities include chronic 
rhinosinusitis (CRS), gastroesophageal reflux disease, obstructive sleep apnea, obesity, and 
depression/anxiety disorder. These comorbidities can hamper diagnosis, reduce treatment 
response, increase acute deterioration, and result in patients receiving excessive treatment. 
Current guidelines emphasize the need for thorough check and correction of comorbidities before 
diagnosing patients as having SA. Detailed information is provided in Supplement S3.
Optimization of treatments in difficult-to-treat asthma
SA is diagnosed when asthma is still poorly controlled a 3-6 months after treatment 
optimization, including both non-pharmacological and pharmacological interventions.
Non-pharmacological interventions
Asthma education is necessary for SA management: lack of information results in poor 
adherence to treatment or under-perception of the asthma severity by patients, resulting in 
poorly controlled asthma. Therefore, to ensure better control, asthmatics should understand 
the nature of the disease, exacerbation signs and symptoms, treatment principles, the 
necessity for regular asthma medication use, avoidance of trigger factors, and self-
management of asthma. Physicians should ensure that patients are aware that asthma is an 
inflammatory airway condition, which rationalizes regular long-term anti-inflammatory 
treatment. It is important to inform patients that several comorbidities and risk factors can 
worsen the disease.
Pharmacological interventions
The combination of ICS and long-acting β2 agonists (LABA) is a mainstay of asthma 
treatment. In patients who do not achieve a well-controlled status with the use of a medium-
dose ICS–LABA combination (GINA step 4), increasing the dose of ICS (a high-dose ICS–
LABA combination) or adding a second controller, such as tiotropium or leukotriene receptor 
antagonists (LTRA), is recommended. Maintenance and reliever therapy with an ICS–
formoterol combination can be considered before moving to GINA step 5 treatment (Fig. 2).
If asthma remains uncontrolled despite use of a high-dose ICS–LABA combination in 
GINA step 5 treatment, other controllers are needed for effective control (Fig. 2). If all 
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of these attempts remain unsuccessful, physicians should consider referring patients to 
asthma specialists for phenotyping and add-on treatment, such as biologics. Biologics are 
helpful for SA with type 2 inflammation. Type 2 inflammation is defined when one of the 
following criteria is satisfied during high-dose ICS: 1) blood eosinophils ≥ 150/μL; 2) sputum 
eosinophils ≥ 2%; 3) FeNO ≥ 20 ppb; and 4) allergen-driven asthma.7 If a patient does not 
show type 2 inflammation (on at least 3 separate assessments), treatment options are very 
limited. Off-label and experimental options for these so-called non-type 2, patients are 
presented further in this paper. Finally, maintenance of low-dose OCS can be added to these 
medications, but adverse effects should be considered.
Phenotype and biomarkers in SA
Phenotype, endotype, and treatable traits
Phenotypes are collections of observable characteristics and can be organized according 
to their associations with specific triggers, patient characteristics, or clinical presentation 
features (Table 3). These phenotypes present as clusters in patients with SA.29 As part of 
the investigative work-up, clinicians endeavor to characterize each patient's asthma. SA is 
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High-dose ICS
Medium-dose ICS-LABA + 2nd controller (e.g. tiotropium, LTRA, or theophylline)
# Before step-up to step 5, consider other treatment options of step 4







High-dose ICS-LABA + 2nd controller (e.g. tiotropium, LTRA, or theophylline)
Add low-dose OCS
Add biologics targeting type 2
inflammation






and consider off-label treatment
Referral to specialist 
Phenotypic assessment
Fig. 2. Pharmacological treatment of severe asthma. Patients with uncontrolled asthma despite the use of a high-dose ICS–LABA combination and an add-on 
second controller (such as tiotropium, LTRA, or theophylline) should be referred to asthma specialists for phenotypic assessment and determination of the use 
of type 2 biologics. Those with type 2 high inflammation are eligible for type 2 biologics. Those with type 2 low inflammation need to be managed with unused 
second controller or an off-label treatment. Finally, OCS could be added as maintenance therapy for patients with severe asthma that is uncontrolled with the 
use of every medication available. 
ICS, inhaled corticosteroids; LABA, long-acting β2 agonists; LTRA, leukotriene receptor antagonists; OCS, oral corticosteroids.
Table 3. Asthma phenotypes
Category Phenotypes
Triggers Atopic/non-atopic, aspirin-exacerbated, infection, exercise, occupational, smoking
Patient characteristics Early/late onset, sex, peri-menopausal onset, race, obesity
Clinical presentation Aggravated by exercise, corticosteroid dependent/resistant, low lung function, less 
reversible airway obstruction, frequent exacerbation
now recognized as a heterogeneous disease driven by multiple underlying pathobiological 
mechanisms (so-called endotypes), which can be described in terms of the cells, cytokines, 
and mediators involved. A deeper understanding of phenotype and endotype has proposed 
“precision medicine” for the management of patients with SA. However, endotypes are not 
fully understood as they are defined by different biological levels (genes, proteins, metabolites, 
cells, organs, and environment). Additionally, endotypes are not mutually exclusive. 
Consequently, it is not easy to implement their use in real practice. Recently, there has been 
a move away from the labeling of airway diseases and toward the identification of phenotypic 
“treatable traits,” linking them to therapeutic approaches.30 These traits can be treatable 
based on phenotypic recognition or deep understanding of the critical endotype recognition.31 
A treatable trait must be clinically important, should be able to be effectively treated to be 
called a “treatable” trait, and needs a trait identification marker for objectively identifying the 
presence of the trait in preparation for targeted therapy (Table 4).30 As an example, a recent 
study examined 24 treatable traits of SA across 3 domains (pulmonary, extra-pulmonary, and 
behavioral/risk factors). This revealed 10 treatable traits, including depression and inhaler-
device polypharmacy, that were significantly associated with an elevated risk of future asthma 
exacerbations.32 Among the treatable traits listed in Table 4, patients with SA expressed more 
pulmonary and extrapulmonary traits than those with non-SA. Allergic sensitization, upper 
airway disease, airflow limitation, eosinophilic inflammation, and frequent exacerbations 
were common in SA. Thus, one can say that a patient “has SA with a degree of fixed airflow 
limitation, likely due to smoking, nasal polyposis, absence of type 2 inflammation, and high 
expression of XX,” rather than “he has asthma,” if XX is a treatable trait. We acknowledge that 
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Table 4. Treatable traits in the European U-BIOPRED adult asthma cohorts and defining criteria
Category Treatable trait Defining criteria
Pulmonary Fixed airway obstruction Post-bronchodilator FEV1/FVC < 0.7
Airway reversibility Post-bronchodilator increases in FEV1 and/or FVC ≥ 12% 
and ≥ 200 mL
Type 2 inflammation Sputum eosinophil proportion ≥ 2% and/or blood 
eosinophils ≥ 450 cells per mL and/or FeNO > 50 ppb
Neutrophilic inflammation Sputum neutrophil proportion > 60%
Cough Asthma Quality of Life Questionnaire Question 12 score ≤ 4 
and/or Sino-Nasal Outcomes Test Question score 4 ≥ 3
Exercise-induced respiratory 
symptoms
Routine physical activity and/or physical exercise as an 
asthma trigger
Sputum Mucus production > 30 mL/day
Extrapulmonary Rhinosinusitis Medical history of “allergic/non-allergic rhinitis active 
and/or sinusitis”
Nasal polyps Medical history of “nasal polyps”
Obese BMI ≥ 25 kg/m2*
Underweight BMI < 18.5 kg/m2*
Obstructive sleep apnea Epworth sleepiness scale score ≥ 11
Gastroesophageal reflux Medical history of “gastroesophageal reflux”
Vocal cord dysfunction Medical history of “vocal cord dysfunction”
Osteoporosis Medical history of “osteoporosis”
Cardiovascular disease Medical history of “cardiac disease”
Eczema Medical history of “eczema”
Atopy Positive skin prick test and/or increased blood IgE
Risk/behavioral Smoking Medical history of “current smoker”
Poor medication adherence Medication Adherence Rating Scale mean score < 4.5
Depression Center for Epidemiologic Studies Depression scale ≥ 16
Anxiety Generalized Anxiety Disorder-7 ≥ 5
Modified from reference 31.
BMI, body mass index; FeNO, fractional exhaled nitric oxide; FEV1, forced expiratory volume in 1 second; FVC, 
forced vital capacity; IgE, immunoglobulin E.
*Based on the Korean criteria for obesity.
the treatable trait approach is more efficient, effective, and safer than the traditional approach, 
and recommend wide use of this approach in clinical practice.
Trait identification markers and biomarkers
Blood eosinophil count is a well-known biomarker of type 2 airway inflammation. Examples 
of biomarkers include everything from laboratory-measured results to questionnaire 
results (e.g., the Hospital Anxiety and Depression Scale, used to recognize psychological 
dysfunctions; Table 4). There is no universally accepted biomarker that is easy to use, 
applicable, and meaningful in clinical practice. The most extensively investigated biomarkers 
are those used to identify type 2 inflammation. They are particularly important in current 
practice as most of the newer biologics target type 2 inflammation. Table 5 summarizes 
the details of currently available biomarkers for type 2 inflammation, such as serum IgE, 
sputum eosinophil count, blood eosinophil count, and FeNO, and their advantages and 
disadvantages. Moreover, a recently updated guideline about SA management from ERS/ATS3 
suggested a cutoff level of blood eosinophil count and FeNO for choosing to use biologics, 
such as anti-IgE and anti-interleukin (IL)-5. By combining these biomarkers, we can get a 
decision chart for phenotype- (or endotype-) based SA management. Biomarkers for non-
type 2 asthma have not been available until now. The pathogenesis of non-type 2 asthma has 
been investigated and revealed little evidence regarding inflammatory molecules, such as 
neutrophils and non-Th2 cytokines (interferon-γ, IL8, IL18, and IL17).
TREATMENT OF SA
Below, we summarize medications that can be added as second controllers in patients in 
whom asthma is poorly controlled by a medium- to high-dose ICS–LABA combination 
in GINA steps 4 or 5. The most preferred second controllers are tiotropium, LTRA, and 
theophylline. Additionally, combining these second controllers with biologics should be 
considered in patients with type 2 inflammation.
Second controllers as add-on treatment to an ICS–LABA combination
Long-acting muscarinic antagonist (LAMA)
LAMA, including tiotropium, are the preferred additional bronchodilator in SA patients with 
a history of exacerbation, because tiotropium improves lung function and asthma symptoms, 
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Table 5. Biomarkers for identifying type 2 inflammation: advantages and disadvantages
Biomarker Advantages Disadvantages
Serum IgE • Easy to measure Does not predict omalizumab responsiveness
• Identifies candidates for omalizumab therapy
Sputum eosinophils •  ERS/ATS recommended to guide treatment, along with clinical criteria Technically challenging to perform; some patients 
cannot provide adequate samples•  Adjusting therapy based on sputum eosinophils was validated for 
reducing exacerbation frequency in adults
Blood eosinophils • Correlated with sputum eosinophilia Optimal cutoff not established
• Easy to measure
•  ≥ 300 cells/μL, ↑ risk of asthma attacks, asthma-related ED visits
• ≥ 400 cells/μL, ↑ rate of severe exacerbations
FeNO • Correlated with sputum and blood eosinophils Not recommended for guiding therapy in patients 
with severe asthma• ≥ 50 ppb, ↑ risk of asthma attacks, asthma-related ED
•  Adjusting therapy based on FeNO reduced the risk of asthma 
exacerbation
Serum periostin • Markers of airway eosinophilia and IL13 activity Not specific to asthma
ED, emergency department; ERS/ATS, European Respiratory Society/American Thoracic Society; FeNO, fractional exhaled nitric oxide; IgE, immunoglobulin E; IL, 
interleukin.
and reduces risk of acute exacerbation (AE), regardless of the baseline characteristics, 
including age, allergic status, and disease duration.33 Moreover, there is accumulating 
evidence of the effects and benefits of LAMA with add-on therapy in SA patients. Tiotropium 
was compared to salmeterol and a placebo in patients with uncontrolled asthma, despite 
medium to high doses of ICS. In 2 replicate, randomized, controlled trials involving patients 
with poorly controlled SA despite the use of standard combination therapy, addition of 
tiotropium significantly increased the time to first exacerbation and provided modest, 
sustained bronchodilation.34 Tiotropium also lowered the rate of AE and improved trough 
FEV1 compared to a placebo.34 Thus, addition of once-daily tiotropium, via a soft mist inhaler, 
to severe, uncontrolled asthma treatment, including a high-dose ICS–LABA combination, 
significantly reduces exacerbation, and improves lung function and symptom control.
Theophylline
Theophylline had been used as a controller before the ICS era. Beyond its weak 
bronchodilator effect, theophylline has anti-inflammatory, immunomodulatory, and 
bronchoprotective effects. Although theophylline is not routinely recommended for mild-
to-moderate asthma in modern treatment, it could be considered as an add-on controller 
in patients with SA. Theophylline is less effective than LABA35 and did not demonstrate 
superiority over LTRA when added to ICS.36
Theophylline administration requires care with monitoring of serum concentrations. The 
clearance of theophylline is increased in younger patients and smokers, and decreased in 
patients with cor pulmonale, cardiac decompensation, hepatic impairment, and elderly 
patients. Concurrent medications that could change theophylline clearance should be checked.
LTRA
Leukotrienes are proinflammatory mediators in tissue, sputum, and blood that contribute to 
eosinophilic inflammation. LTRA provides an additional bronchodilator effect when added 
to ICS and/or LABA.37 The median number of asthma exacerbation incidents per patient 
decreased from 1.6 to 1.2 per year when montelukast was added to SA treatment in elderly 
patients.38 In contrast, in a study of 72 adults with SA receiving an ICS–LABA combination, 
some of whom were also on OCS, the addition of montelukast did not improve the clinical 
outcomes over 14 days.39 LTRA has advantages as an oral agent when used once or twice daily. 
Additionally, it has an excellent safety profile and a good therapeutic index.
Type 2 biologics therapy
There are currently 3 types of biologics for the treatment of SA patients with type 2 
inflammation: anti-IgE, anti-IL5/anti-IL5 receptor (R), and anti-IL4Rα (Table 6). These 
medications are specific for the type 2 SA phenotype. The target population should be 
selected carefully based on inflammatory phenotypes. If used in appropriate patients, they 
may modify underlying pathogenic mechanisms and prevent disease progression.
Anti-IgE antibody
1) Omalizumab
Omalizumab is a recombinant, humanized, monoclonal IgG antibody against IgE. It binds to 
free, circulating IgE rather than mast cell-bound IgE, decreasing the total body IgE fraction 
which down-regulates FcεRI on the mast cell surface. In the pivotal INNOVATE study,40 
patients (age: 12-75 years) with inadequately controlled asthma despite a high-dose ICS–LABA 
combination, with reduced lung function and asthma exacerbations, randomly received 
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omalizumab (compared to placebo) for 28 weeks. All patients had atopic asthma and a serum 
total IgE level of 30–700 IU/mL and FEV1 40%–80% of predicted. Total asthma exacerbation, SA 
exacerbation, and emergency department visit rates were markedly decreased.
Omalizumab was approved for use in Korea by the Ministry of Food and Drug Safety (MFDS) 
in 2007. Currently approved indications of omalizumab are detailed in Table 6. Dosing should 
not be adjusted based on total IgE levels during treatment or <1 year following interruption 
of therapy. A maximum amount of 150 mg should be administered at a single injection site to 
avoid local reactions. Therapy should not be initiated during AE of asthma, nor should it be 
self-administered or administered outside of a medical setting, due to the risk of anaphylaxis.
Previous studies have shown that omalizumab is effective in only about 60%–70% of SA 
patients. If it is going to be effective, it usually works within 4 months,41 although it is unclear 
how long patients should remain on omalizumab. Studies have shown that, after more than 
2 years of treatment, the condition of about half of patients with asthma did not worsen even 
after stopping omalizumab. It is currently advised that, for patients with a good response, a 
trial withdrawal of the biologic should be considered after at least 12 months of treatment, and 
only if asthma remains well-controlled on medium-dose ICS therapy and there is no further 
exposure to a previous, well-documented allergic trigger, omalizumab can be discontinued.
Treatment with omalizumab was well-tolerated in several clinical trials. Through a post-
marketing investigation, omalizumab could cause anaphylaxis with a probability of 1/1,000.42 
A significant proportion of anaphylactic reactions was delayed in onset and exhibited 
protracted symptom progression; 61% of these reactions occurred within the first 2 hours 
after the first 3 injections; 14% occurred within 0.5 hours after the 4th or later injection.43 
Therefore, it has been recommended that patients should be observed for 2 hours after the 
first 3 injections of omalizumab and for 30 minutes after subsequent injections.
In addition to omalizumab, other anti-IgE drugs (ligelizumab, quilizumab, XmAb7195, and 
MEDI4212) are currently undergoing clinical trials.44
Anti-IL5 and anti-IL5R antibody
1) Mepolizumab
Mepolizumab is a humanized monoclonal antibody that inhibits IL5 selectively and targets 
eosinophils specifically. In the DREAM study, mepolizumab reduced the frequency of AE in 
severe eosinophilic asthma (SEA), which was defined as 1 or more following criteria in the 
previous year: sputum eosinophils ≥ 3%, FeNO ≥ 50 ppb, blood eosinophils ≥ 300/μL, and 
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Table 6. Currently approved indications of biologics for severe asthma in Korea
Biologics Action Dose Interval (wk) Route Indication
Omalizumab (Xolair®) Anti-IgE 0.016 mg/kg per IU 2 or 4 SC ≥ 6 years old; positive allergy testing (allergic asthma);  
IgE: 30–700 IU/mL
Mepolizumab (Nucala®) Anti-IL5 100 mg 4 SC ≥ 18 years old; AEC ≥ 150 cells/μL or ≥ 300 cells/μL  
at least once a year
Reslizumab (Cinqair®) Anti-IL5 3 mg/kg 4 IV ≥ 18 years old; AEC ≥ 400 cells/μL
Benralizumab (Fasenra®) Anti-IL5R 30 mg 8* SC ≥ 18 years old; severe eosinophilic asthma
Dupilumab (Dupixent®) Anti-IL4Rα 200 mg† 2 SC ≥ 12 years old; AEC ≥ 150 cells/μL or FeNO ≥ 25 ppb
300 mg‡ 2 SC With OCS-dependent or moderate-to-severe atopic dermatitis
SC, subcutaneous; IV, intravenous; IgE, immunoglobulin E; IL, interleukin; AEC, absolute blood eosinophil count; FeNO, fractional exhaled nitric oxide; OCS, oral 
corticosteroids.
*Every 4 weeks for the first 3 doses, followed by every 8 weeks for maintenance; †For the first cycle, 400 mg (two 200 mg injections); ‡For the first cycle, 600 mg 
(two 300 mg injections).
prompt deterioration of asthma after 25% or less reduction in regular ICS or OCS.45 In the 
MENSA study, the AE rate reduced by 53% and the mean FEV1 improved by 98 mL with the 
administration of subcutaneous (SC) mepolizumab.46 In the SIRIUS study, mepolizumab led 
to a 50% reduction in OCS dosage and reduced the AE rate by 32% in SEA, and improved 
health-related quality of life in the MUSCA trial.47,48
Mepolizumab (100 mg, SC, monthly) was approved in Korea by the MFDS in 2016 (Table 6). 
However, there is no clear guideline on how long treatment should continue. A clinical response 
to mepolizumab is usually observed within 4 months; the safety profile is similar to a placebo in 
clinical trials and even after long-term exposure (up to 4.5 years), it can be continued indefinitely 
if a clinical response is achieved.49 To date, there is no definite evidence of the development of 
neutralizing anti-drug antibodies to IL5. Mepolizumab should not be used to treat AE.
2) Reslizumab
Reslizumab is a humanized, monoclonal antibody of IgG4 subtype against IL5, with a similar 
mechanism as mepolizumab. A phase 2, randomized, placebo-controlled, multicenter trial 
(NCT02559791) demonstrated that intravenous (IV) reslizumab (3.0 mg/kg) significantly 
decreased sputum eosinophils and improved asthma symptoms in patients with SA and 
sputum eosinophils ≥ 3%.50 In phase 3 trials, 2 duplicate international, double-blind, 
parallel-group, randomized, placebo-controlled trials, patients who had blood eosinophils ≥ 
400 cells/μL or ≥ 1 AE in the previous year had a significant reduction in AE frequency after 
receiving reslizumab (NCT01287039 and NCT01285323).51 Additionally, reslizumab improved 
lung function, asthma control and symptoms, and quality of life.52 No study to date has 
demonstrated an OCS-sparing effect. Weight-adjusted IV reslizumab administration showed 
more effective attenuation in sputum/blood eosinophils, with an improvement of asthma 
control, than fixed-dose SC mepolizumab.53
Although common adverse reactions were similar to those of placebo, 3 anaphylaxis cases 
occurred among 1,611 patients during randomized controlled trials.50,51 Therefore, this drug 
has a black box warning from the US Food and Drug Administration.51 Although it shows 
favorable long-term safety and efficacy (up to 2 years), blood eosinophil levels appear to 
return to previous levels after stopping, by approximately 4 months after the last dose.54 
Reslizumab (3 mg/kg, IV, monthly) was approved in Korea by MFDS in 2017 (Table 6).
3) Benralizumab
Benralizumab, a humanized monoclonal antibody against the alpha subunit of IL5R, on the 
immune cell surface, induces rapid and nearly complete depletion of eosinophils by natural 
killer cell-mediated cellular cytotoxic reactions. In the phase 3 SIROCCO study, benralizumab 
reduced AE, improved prebronchodilator FEV1, and improved asthma symptoms in patients 
who had blood eosinophils ≥ 300 cells/μL or ≥ 2 AE in the previous year55; this was replicated 
in Korean patients and other trials.56,57 In the ZONDA trial, benralizumab reduced OCS use 
by 75% from baseline and the annual AE rate by 70%.58 In a matching-adjusted indirect 
comparison, benralizumab and mepolizumab showed similar efficacy.59 The phase 3 BORA 
trial showed the safety and efficacy of benralizumab over 2 years. The therapeutic effect of 
benralizumab was maintained for up to 2 years. The most common AE was worsening asthma, 
with no helminth infection cases reported.60 The eosinophil depletion was maintained 
through the 2nd year, and blood eosinophil counts began to increase after treatment 
discontinuation.60 Benralizumab was approved by the MFDS in 2019 for the treatment of SEA 
in Korea, at 30 mg SC every 2 months (every 4 weeks for the first 3 doses) (Table 6).
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Anti-IL4Rα antibody
1) Dupilumab
Dupilumab is a fully human monoclonal IgG4 antibody to the alpha subunit of IL4R, which 
is activated by IL4 and IL13. Dupilumab blocks IL4Rα to inhibit the signaling effects of IL4 
and IL13, which play a crucial role in asthma and are produced mainly by CD4+ Th2 cells and 
ILC2s. In a phase 2a study, dupilumab treatment reduced the AE rate by 87%, as well as the 
concentration of FeNO and total IgE, in patients with persistent, moderate-to-SA (blood 
eosinophil counts of ≥ 300 cells/μL or sputum eosinophil ≥ 3%).61 In the phase 2b trial, 
dupilumab reduced the AE rate, by 70%, and FeNO, and improved FEV1, quality of life, and 
asthma control in patients with uncontrolled, persistent asthma, who were on a moderate- 
to high-dose ICS–LABA combination, irrespective of the baseline eosinophilic count.62 A 
phase 3 trial (the Liberty Asthma QUEST study; 52 weeks) confirmed the earlier findings, 
such as the improvement of FEV1, asthma control, and quality of life, and reduction of severe 
AE, irrespective of the baseline eosinophil count or any other biomarkers. However, it was 
observed that it was more effective for cases with a higher blood eosinophil count.63
Dupilumab was approved as maintenance therapy for patients ≥ 12 years old with SEA 
(suggested blood eosinophil counts ≥ 150 cells/μL or FeNO ≥ 25 ppb) or with OCS-dependent 
asthma by the US Food and Drug Administration in 2018. Dupilumab was recently approved 
by the MFDS as a treatment for patients with SEA in 2020 (for first cycle 400 or 600 mg, 
followed by 200 or 300 mg every 2 weeks) (Table 6). The most common adverse effects were 
injection-site reactions and upper respiratory infections.62 Eosinophilia was found in 1.2%; 
2 cases suffered from worsening of hypereosinophilia and chronic eosinophilic pneumonia, 
including a fatality due to pneumonia.63
Future drugs in development
1) Anti-thymic stromal lymphopoietin (TSLP) antibody (Tezepelumab)
Tezepelumab is a humanized monoclonal antibody specific for the epithelial cell-derived 
cytokine, TSLP. A phase 2 trial showed that it could reduce the AE rate and improve FEV1 as 
compared to placebo, regardless of blood eosinophil counts.64
2)  Chemoattractant receptor-homologous molecule expressed on Th2 lymphocytes (CRTH2) 
antagonist (prostaglandin D2 [PGD2] receptor 2 [DP2] antagonist)
PGD2, generated by hematopoietic prostaglandin D synthase, acts on G protein-coupled 
receptors, including the CRTH2 and DP1. Fevipiprant, a PGD2 antagonist, binds to DP2 (also 
known as CRTH2), which mediates the migration of Th2 cells, stimulates them to produce 
type 2 cytokines, such as IL4, IL5, and IL13, and affects the cytokine release from ILC2s.65 
Fevipiprant reduces eosinophilic airway inflammation and is well tolerated in patients with 
persistent moderate-to-SA and sputum eosinophilia despite ICS therapy.
3) Anti-IL33 antibody (Etokimab, ANB020)
IL33 plays an important role in type-2 innate immunity via the activation of allergic 
inflammation through its receptor ST2. Phase 2 trials, targeting the IL33 and IL33/ST2 axis 
are currently ongoing.
Selection of biologics for SA
Selection of the most appropriate drug among the currently approved biologics for patients 
with SA is challenging. No head-to-head comparisons between currently available biologics 
have been conducted. There are no useful biomarkers for predicting or monitoring treatment 
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responses. Thus, factors such as the mechanism of action of certain drugs, blood/sputum 
eosinophil levels, serum IgE levels, FeNO levels, and atopic status of asthma patients, as well 
as the cost of the drugs, should be considered when selecting biologics. For patients with 
allergic asthma, anti-IgE antibody (omalizumab) is recommended in the first place among 
biologics. Blood eosinophil counts ≥ 260 cells/μL or FeNO ≥ 19.5 could be used as biomarkers 
predicting a good response to anti-IgE treatment.3 For eosinophilic asthmatic patients 
(suggested blood eosinophil counts ≥ 150 cells/μL) with a history of AE, anti-IL5/5R therapy 
may be considered as the first choice. IL4Ra could be considered as a treatment option for 
severe eosinophilic type 2 asthma or patients requiring maintenance OCS.
Assessment of treatment response to biologics
Evaluation of therapeutic response to biologics is important, and we recommend it after 3–4 
months of use. Unfortunately, at present, there are no criteria and/or biomarkers of a good 
response. To determine response, we need consider AEs, symptom control, lung function, OCS 
sparing, and patient satisfaction collectively. Although the GINA guidelines on SA recommend 
extending trials to 6–12 months if the treatment response is difficult to assess after use of 
biologics for 3–4 months,7 evidence is scarce and further studies are required. If patients 
have shown a good response to biologics, the first step is to reduce OCS carefully, and then 
stop other add-on therapy by evaluating asthma control at an interval of 3–6 months. Inhaler 
use should be maintained at least at medium-dose ICS and patients need to be informed to 
avoid stopping the inhaler use even if symptoms improve. Evidence on when to discontinue 
biologics remains insufficient. On the other hand, if patients are non-responders, the following 
should be considered. First, treatable trait, including the type 2 high inflammation phenotype 
and comorbidity, should be reviewed. Then, clinicians can attempt to switch different type 2 
targeted biologics, although the timing of the drug switch has not yet been established. Another 
option might be combination therapy with 2 or more biologics in patients who have severe 
eosinophilic and allergic asthma despite receiving add-on therapy with a biologic agent.
Off-label treatments and therapeutic procedures
Macrolides
Macrolides have been considered as a therapeutic option for asthma due to their anti-
bacterial and immunomodulating actions. There have been several randomized trials using 
clarithromycin and azithromycin for refractory asthma patients. Clarithromycin therapy 
(500 mg, twice daily) for 8 weeks, in a study of 23 SA patients, reduced sputum IL8 levels, 
neutrophil numbers, and improved the quality of life scores as compared to placebo.66 The 
AZISAST study used azithromycin 250 mg once daily for 26 weeks in 55 SA patients, and 
the AMAZES study used azithromycin 500 mg, 3 times a week, for 48 weeks in 213 partly 
controlled asthma patients.67 They showed reduction in AE and reduction in severe AE in 
those with non-eosinophilic SA (blood eosinophilia ≤ 200/μL). Although a Cochrane review 
published in 2015 was inconclusive because of the low quality of evidence,68 macrolides 
could be an additional therapy in SA patients. However, increasing antibiotic resistance, QT 
prolongation, and hearing loss should be considered.
Roflumilast
Roflumilast is known to exert an anti-inflammatory effect, decreasing neutrophilic and 
eosinophilic inflammation. According to Meltzer and colleagues,69 roflumilast provided 
additional improvements in FEV1 when given with ICS. In a phase 2 trial, the combination 
of roflumilast with montelukast improved lung function and asthma control, as compared to 
montelukast alone, in moderate-to-SA.70
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Imatinib
In a randomized trial, imatinib decreased airway hyper-responsiveness, mast cell counts, and 
tryptase release in patients with SA.71 A similar drug, masitinib (c-Kit/PDGFR tyrosine kinase 
inhibitor) improved disease control in severe CS-dependent asthmatics.72
Bronchial thermoplasty (BT)
Airway smooth muscles play multiple roles in asthma pathogenesis, including regulation of 
bronchial tone, immunomodulation, and extracellular matrix deposition. BT ablates airway 
smooth muscles by radiofrequency energy. BT resulted in significant improvements in FEV1, 
the Asthma Control Questionnaire score, and a reduction of severe AE in SA patients, which 
remained over 52 weeks to 5 years.73
SCS
CS is effective in targeting numerous elements of the type 2/eosinophilic inflammatory 
pathway. The key mechanism is depletion of circulating eosinophils caused by ICS-
unresponsive recruitment signals of the airway mucosa and resulting in a reduced response 
to ICS. To date, OCS have been widely used as a maintenance treatment in SA. However, 
chronic OCS use has serious side-effects. Moreover, CS-dependent asthma is associated with 
an increased risk of mortality22; therefore, CS should be considered as the last controller.
SPECIFIC SITUATIONS
EGPA
EGPA is a rare systemic necrotizing vasculitis accompanying asthma, blood, and tissue 
eosinophilia. The exact prevalence of EGPA in Korea is not known particularly in the SA 
population. However, a retrospective analysis from a single center in Korea showed that 
the respiratory tract (bronchial asthma) was the most commonly involved organ, and its 
involvement was associated with a more favorable outcome.74 EGPA occurs in a minority of 
SA patients. However, EGPA should be considered when dealing with severe uncontrolled 
asthma as these patients require additional treatment, such as immunosuppressants and 
OCS. Mepolizumab in high doses (300 mg every 4 weeks) can be used to treat EGPA.75
Aspirin-exacerbated respiratory disease (AERD)
AERD is characterized by asthma, CRS with nasal polyps, and hypersensitivity to aspirin/
nonsteroidal anti-inflammatory drugs (NSAID). A recent meta-analysis reported the 
prevalence of AERD as 7% in adult patients with asthma and 14% in patients with SA.76 The 
risk of uncontrolled asthma, SA, and AE is reported to be higher in patients with AERD than 
in those with aspirin-tolerant asthma. Identifying patients with AERD is important because 
of its high morbidity. Additionally, education on aspirin/NSAID avoidance and trialing of 
other potential therapeutic options are needed.
ABPA
ABPA is caused by hypersensitivity to Aspergillus fumigatus. It manifests as poorly controlled 
asthma, recurrent pulmonary infiltrates, and bronchiectasis. ABPA is also a risk factor 
for accelerated loss of lung function. Therefore, recognizing ABPA is important to 
improve patient symptoms and to delay the development or prevention of bronchiectasis. 
Sensitization to Aspergillus without other characteristics of ABPA in SA is termed SA with 
fungal sensitization; one-third to one-half of SA patients have fungal sensitization mostly to 
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A. fumigatus. Patients with asthma who display fungal sensitization are more likely to have SA. 
ABPA treatment consists of anti-inflammatory therapy with CSs and anti-fungal treatment 
to reduce the fungal load in the airways. SCS is recommended over several months, with an 
initial dose of 0.5 mg/kg of prednisone and tapered over 6-8 weeks. Although SCS is highly 
efficacious in ABPA management, almost 50% of patients relapse when the dose is tapered, 
and 20%–45% become CS-dependent. Anti-fungal therapy with itraconazole (200 mg qd) is 
recommended as a second-line treatment.
The total IgE level in ABPA patients is usually high. Therefore, omalizumab, which acts 
against serum free IgE, has been used for ABPA treatment. Recent systematic reviews of case 
reports of omalizumab treatment in ABPA showed that it reduced FeNO, total IgE, AE, and 
SCS, but not lung function.77 Double-blind placebo-controlled trials are needed to establish 
the efficacy and safety of omalizumab treatment in ABPA.
Asthma–COPD overlap (ACO)
ACO is a condition in which the clinical features of asthma and COPD coexist in a patient.7 
Despite considerable effort to define ACO, there are no definite diagnostic criteria for this 
disease.7 Accordingly, the prevalence varies widely, depending on the criteria applied, and 
the clinical outcomes are inconsistent. However, ACO patients are generally considered to 
be more symptomatic, experience more frequent exacerbations, and have higher mortality 
than patients with asthma. Unfortunately, there have been no large-scale treatment trials 
for ACO patients. Therefore, the treatment strategy for ACO patients is not well established. 
Currently, an ICS–LABA combination is generally recommended as an initial treatment 
for ACO. However, given that the patients with ACO have more symptoms and frequent 
exacerbations, a significant proportion of patients are thought to be uncontrolled with an 
ICS–LABA combination.
A post hoc analysis of the PROSPERO study showed that ACO patients receiving omalizumab 
over 48 weeks had improved treatment outcomes in terms of AE and ACT scores similar 
to those of patients without ACO.78 In the post hoc subgroup analyses, using data from the 
DREAM and the MENSA phase III studies on SA, mepolizumab was effective in preventing 
AE in asthmatic patients who had COPD features (≥40 years of age, fixed airflow limitation, 
FEV1 < 80%, and poor bronchodilator response) and smoking history (former smoker 
≤ 10 years). In contrast, patients who were enrolled in a study demonstrating the effect 
of mepolizumab on eosinophilic COPD patients (100 mg in METREX, 100 or 300 mg in 
METREO) had some asthma features (elevated blood eosinophil count and use of high-dose 
ICS therapy).79 Therefore, mepolizumab may be recommended for improving the treatment 
outcomes of ACO patients in some cases. A post hoc analysis using the data from a phase 2b 
study on the clinical efficacy of dupilumab in patients with uncontrolled, persistent asthma 
revealed that about 12% of patients had COPD features, such as fixed airflow limitation with 
FEV1 < 80% and smoking history ≤ 10 years. The preliminary study results showed significant 
improvements in FEV1 and reduced frequent exacerbations with the use of dupilumab (300 
mg every 2 weeks). This may also apply to patients with ACO.
Future direction of SA diagnosis and management in Korea
The development of type 2 biologics has led to an era of precision medicine. It also requires 
the physician to select the patients who would benefit most from particular drugs. To this 
end, accurate diagnosis of SA, and phenotypes and treatable traits need to be performed 
systematically. If a primary care physician does not have the capability to diagnose and manage 
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uncontrolled or difficult-to-treat asthma, or encounters suspected SA patients, referral to an 
asthma specialist should be made. A SA clinic needs to enhance its ability to diagnose SA and 
comorbidities via a cooperative, multidisciplinary approach. Additionally, standardized protocols 
for phenotyping and assessing SA are required. We hope that this opinion paper will facilitate 
identification of patients with SA for referral and setting up SA clinics in referral hospitals.
While type 2 biologics have been approved and are available in clinical practice, they are not 
reimbursed by the public health insurance in Korea as yet. Most patients with SA cannot 
afford the high cost of biologics, and even those with very good responses to biologics 
often refuse to maintain biologic treatment because of economic reasons. Thus, a stratified 
approach is needed to use these highly expensive medications wisely in the management of 
SA. Making a new diagnostic code for the diagnosis of SA and reimbursement of biologics 
could be an option. Moreover, funds should be focused on the care of SA patients.
CONCLUSION
Difficult-to-treat and SA is associated with significant morbidity and mortality rates. A 
comprehensive and systematic approach is needed to manage uncontrolled asthma and to 
define difficult-to-treat asthma and SA. Applying the concept of treatable traits is a practical 
tool for managing SA. Since biologics targeting type 2 inflammation are available in clinical 
practice, physicians should consider referring patients with SA to specialists appropriately 
and to assess phenotypes for starting biologics. Moreover, novel treatments are needed to 
manage SA that is unresponsive to currently available medications.
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